ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe

/in

New investor, Partners in Equity – joins existing investors Health Innovations, INKEF Capital LSP and Invest-NL Proceeds will be used for commercial European launch of updated Kaleido insulin patch pump system including automated insulin delivery (AID) or closed loop December 16, 2021, Utrecht, The Netherlands – ViCentra, the company behind Kaleido, the world’s smallest and lightest wearable […]

Read more

Depixus Raises USD 35.4M in Series A Financing

/in

The financing will support development of a commercial instrument system based on the company’s proprietary and disruptive MAGNA™ technology. MAGNA™ is set to unlock the field of dynamic genomics. Funds raised from a global investor syndicate led by Lansdowne Partners and Bpifrance and supported by funds bringing additional experience in the life science sector. Paris, […]

Read more

Biocomposites year of international growth and product advancement

/in

Expansion into new geographies and enhanced approval for STIMULAN to treat bacterial infection Keele, UK, 15 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to provide the following business update. Read more…

Read more

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

/in

Egetis concludes, based on recent regulatory interactions, that available Triac Trial I data together with recently published long-term data are sufficient for a Marketing Authorisation Application in Europe Having all clinical data required for regulatory submission already at hand significantly reduces the remaining risk for Emcitate Revised submission timelines will be communicated as soon as […]

Read more

EXACT Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021

/in

OSLO/LONDON: 13 DECEMBER, 2021: EXACT Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that its Interim Chief Executive Officer and Chief Financial Officer, Dominic Moreland and Chief Medical Officer, Dr Hilary McElwaine-Johnn will present a corporate overview via […]

Read more
© Optimum Strategic Communications.